

H.R.133 - Mandating Exclusive Review of Individual Treatments (MERIT) Act

118th Congress (2023-2024) |

Sponsor:

Committees:

Committee Meetings:

Latest Action:

Tracker:

[Rep. Buchanan, Vern \[R-FL-16\]](#) (Introduced 01/09/2023)

House - Energy and Commerce; Ways and Means

[12/05/23 2:00PM](#) [11/15/23 10:00AM](#) [09/19/23 10:00AM](#) [\(All Meetings\)](#)

House - 12/19/2024 Placed on the Union Calendar, Calendar No. 779. [\(All Actions\)](#)

Introduced

Passed House

Passed Senate

To President

Became Law

Summary(1) **Text(1)** Actions(13) Titles(2) Amendments(0) Cosponsors(6) Committees(2) Related Bills(0)

Listen

There is one version of the bill. **Text available as:** XML/HTML | [XML/HTML \(new window\) \(3KB\)](#) | [TXT \(2KB\)](#) | [PDF \(224KB\)](#)

Shown Here:
Introduced in House (01/09/2023)

118TH CONGRESS
1ST SESSION

H. R. 133

To amend title XVIII of the Social Security Act to clarify the use of the national coverage determination process under the Medicare program.

IN THE HOUSE OF REPRESENTATIVES

JANUARY 9, 2023

Mr. BUCHANAN (for himself, Ms. BARRAGÁN, and Ms. SALAZAR) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to clarify the use of the national coverage determination process under the Medicare program.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Mandating Exclusive Review of Individual Treatments (MERIT) Act”.

SEC. 2. CLARIFICATION ON MEDICARE NATIONAL COVERAGE DETERMINATION PROCESS.

Section 1862(a) of the Social Security Act ([42 U.S.C. 1395y\(a\)](#)) is amended by adding at the end the following new sentence: “For purposes of paragraph (1)(E), in the case of research conducted pursuant to section 1142, the determination of whether a drug or biological is reasonable and necessary to carry out the purposes of section 1142 shall be made with respect to each drug or biological involved and not with respect to a class of drugs or biologicals.”.
